<DOC>
	<DOCNO>NCT01673737</DOCNO>
	<brief_summary>Primary Objective : Part A - Monotherapy : - To determine maximum tolerate dose ( MTD ) SAR260301 administer monotherapy either twice daily schedule , patient advance solid tumor lymphomas . Part B - Combination : - To determine maximum tolerate dose ( MTD ) SAR260301 administer combination recommend standard dosage vemurafenib patient unresectable / metastatic v-raf murine sarcoma viral oncogene homolog B1 ( BRAF ) -mutated melanoma . Secondary Objectives : - To characterize overall safety tolerability profile SAR260301 administer monotherapy ( Part A ) combination vemurafenib ( Part B ) . - To characterize pharmacokinetic ( PK ) profile SAR260301 administer monotherapy ( Part A ) combination vemurafenib ( Part B ) well vemurafenib PK combination SAR260301 ( Part B ) - To evaluate food effect SAR260301 PK ( Part A ) - To assess preliminary antitumor activity accord Response Evaluation Criteria Solid Tumors ( RECIST 1.1 criterion ) . - To assess preliminary antitumor activity use volumetric compute tomography ( CT ) magnetic resonance imaging ( MRI ) - To evaluate pharmacodynamic ( PD ) effect SAR260301 blood tumor . - To evaluate PK/PD relationship . - To identify recommended phase 2 dose SAR260301 combination vemurafenib ( RP2D ) ( Part B ) - To assess potential induction effect SAR260301 cytochrome P450 ( CYP ) isoenzyme 3A ( CYP3A ) ( Part A )</brief_summary>
	<brief_title>A Phase I/Ib Trial Evaluation SAR260301 Monotherapy Combination With Vemurafenib Patients With Various Advanced Cancer</brief_title>
	<detailed_description>Study duration one patient include period inclusion ( screening period ) 4 week , treatment period least 4 week , end-of-study visit 30 day follow last administration study drug . The patient may continue treatment disease progression , unacceptable toxicity willingness stop , follow minimum 30-days follow-up .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Inclusion criterion : Age ≥18 year old Locally advanced metastatic solid tumor disease well lymphoma alternative therapy available ( Part A ) Unresectable / metastatic BRAFmutated melanoma , progress BRAF inhibitor 4 month treatment partial response ( &lt; 50 % change tumor volume ) 4 month treatment ( Part B ) vemurafenib naive ( Part B escalation phase ) : anterior scan must available patient receive BRAF inhibitor prior entry study . At least one measurable lesion RECIST v1.1 Archived primary tumor biopsy surgical specimen , biopsy recurrence metastasis , request subject predictive marker response analysis . Exclusion criterion : ECOG performance status &gt; 1 Concurrent treatment anticancer therapy Patient reproductive potential ( female male ) agree use accept effective method contraception study treatment period least 6 month follow completion study treatment . Pregnancy breastfeed Any malignancy related immunodeficiency virus ( HIV ) solid organ transplant ; history know HIV , unresolved viral hepatitis . Subjects brain metastases noncentral nervous system ( CNS ) primary tumor exclude lesion large 1 cm long dimension , symptomatic change size late scan compare previous scan . Subjects must require corticosteroid treatment receive treatment brain metastasis least one month prior study entry . Inadequate haematological function . Inadequate renal function . Inadequate liver function . Nonresolution prior treatment related toxicity &lt; Grade 2 , except alopecia accord National Cancer Institute Common Terminology Criteria Adverse Events ( NCI CTCAE ) v4.03 . Any major surgery within last 28 day . History congenital platelet function defect bleed diathesis . Abnormal platelet function use platelet function assay PFA 100® include aggregation time &gt; 122 second use collagen/ADP cartridge , and/or &gt; 183 second use collagen/epinephrine cartridge . Current use aspirin , clopidogrel , ticlopidine , prasugrel ticagrelor . Abnormal coagulation parameter : Prothrombin time ( PT ) / international normalize ratio ( INR ) activate partial thromboplastin time ( aPTT ) &gt; 1.3X ULN . Prophylactic therapeutic anticoagulant permit . Any follow within 6 month prior study enrolment : peptic ulcer disease , erosive oesophagitis , gastritis , infectious inflammatory bowel disease , diverticulitis , GI perforation , intestinal obstruction GI hemorrhage . Patients history chronic renal disease , interstitial nephritis , uncontrolled unresolved acute renal failure . Hemoptysis within past 3 month . Patients know Gilbert 's syndrome . Prior hypersensitivity reaction severe dermatologic reaction Steven 's Johnsons syndrome toxic epidermal necrolysis ( TENS ) vemurafenib Part B. Uveal melanoma new primary malignancy Part B Prior history ongoing uveitis Mean QTc interval &gt; 470 msec ( use QTcF formula ) clinically significant QTc prolongation , history Torsade de Pointes malignant arrhythmias conduction disturbance . Other clinically significant ECG abnormality include 2nd degree ( Mobitz Type II ) , familial history long QT syndrome 3rd degree atrioventricular block . Congestive heart failure Uncontrolled untreated hypertension Uncorrectable serum abnormality follow electrolyte : potassium , magnesium calcium . Medical condition require concomitant administration strong CYP3A4 inhibitor inducer 2 week prior study treatment 5 elimination halflife drug , whichever long . Medical condition require concomitant administration medication narrow therapeutic window metabolize CYP1A2 CYP2D6 , dose reduction consider . Medical condition require concomitant administration medication susceptible prolong QTc interval . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>